M. Covolan, Luiza Tsuruda, D. Silva, David Barbosa, R. Pasa, K. Kavalco, F. Menegídio
{"title":"Pediatric clinical trial profile for COVID-19 at ClinicalTrials.gov: a systematic review","authors":"M. Covolan, Luiza Tsuruda, D. Silva, David Barbosa, R. Pasa, K. Kavalco, F. Menegídio","doi":"10.25060/residpediatr-2021.v11n2-614","DOIUrl":null,"url":null,"abstract":"INTRODUCTION: COVID-19 is an extremely serious infectious disease. However, few studies have focu-sed on the drug treatment of pediatric patients affected by COVID-19. OBJECTIVE: Thus, this study conducted a review of clinical trials registered in the Clinical Trials database on drug treatment in pe-diatric patients with COVID-19. METHODS: A systematic search was conducted in the Clinical Trials database (https://clinicaltrials.gov/) using the web tracking technique to collect registered clinical tri-als that conducted drug treatment in pediatric patients aged 0 to 17 years. After the drugs used were identified, their dosage and other pertinent information were obtained from the DrugBank databases (https://go.drugbank.com) and the DrugBase (https://www.drugbase.de). RESULTS: Eight clinical trials were found in the research, classified as completed and 34 in progress, aimed at pediatric patients. The United States was the country that most research involving the drug use in patients with pedia-tric COVID-19. Hydroxychloroquine was the most observed drug in the treatment of pediatric pa-tients, followed by remdesivir. An increase in phase 3 and randomized trials was also observed among ongoing research when compared to completed research. CONCLUSION: Compared to adults, pedia-tric COVID-19 has distinct treatment needs. Thus, it is important to complete the clinical trials de-scribed in the present study, in addition to more randomized clinical trials, before any therapy or other objects related to the clinical management processes for COVID-19 can be properly recom-mended and applied in pediatric treatment.","PeriodicalId":338092,"journal":{"name":"Residência Pediátrica","volume":"110 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Residência Pediátrica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25060/residpediatr-2021.v11n2-614","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION: COVID-19 is an extremely serious infectious disease. However, few studies have focu-sed on the drug treatment of pediatric patients affected by COVID-19. OBJECTIVE: Thus, this study conducted a review of clinical trials registered in the Clinical Trials database on drug treatment in pe-diatric patients with COVID-19. METHODS: A systematic search was conducted in the Clinical Trials database (https://clinicaltrials.gov/) using the web tracking technique to collect registered clinical tri-als that conducted drug treatment in pediatric patients aged 0 to 17 years. After the drugs used were identified, their dosage and other pertinent information were obtained from the DrugBank databases (https://go.drugbank.com) and the DrugBase (https://www.drugbase.de). RESULTS: Eight clinical trials were found in the research, classified as completed and 34 in progress, aimed at pediatric patients. The United States was the country that most research involving the drug use in patients with pedia-tric COVID-19. Hydroxychloroquine was the most observed drug in the treatment of pediatric pa-tients, followed by remdesivir. An increase in phase 3 and randomized trials was also observed among ongoing research when compared to completed research. CONCLUSION: Compared to adults, pedia-tric COVID-19 has distinct treatment needs. Thus, it is important to complete the clinical trials de-scribed in the present study, in addition to more randomized clinical trials, before any therapy or other objects related to the clinical management processes for COVID-19 can be properly recom-mended and applied in pediatric treatment.